Dose-dependent decrease of platelet activation and tissue factor by omega-3 polyunsaturated fatty acids in patients with advanced chronic heart failure

Deddo Moertl; Rudolf Berger; Alexandra Hammer; Raisa Hutuleac; Renate Koppensteiner; Christoph W. Kopp; Sabine Steiner

doi:10.1160/TH11-03-0169

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2011; 106(03): 457-465
DOI: 10.1160/TH11-03-0169

Platelets and Blood Cells

Schattauer GmbH

Dose-dependent decrease of platelet activation and tissue factor by omega-3 polyunsaturated fatty acids in patients with advanced chronic heart failure

Authors

Deddo Moertl

¹Division of Cardiology, Department of Internal Medicine II, Medical University of Vienna, Vienna, Austria

²Department of Internal Medicine III (Cardiology), Landesklinikum St. Poelten, St. Poelten, Austria
Rudolf Berger

¹Division of Cardiology, Department of Internal Medicine II, Medical University of Vienna, Vienna, Austria
Alexandra Hammer

³Division of Angiology, Department of Internal Medicine II, Medical University of Vienna, Vienna, Austria
Raisa Hutuleac

¹Division of Cardiology, Department of Internal Medicine II, Medical University of Vienna, Vienna, Austria
Renate Koppensteiner

³Division of Angiology, Department of Internal Medicine II, Medical University of Vienna, Vienna, Austria
Christoph W. Kopp

³Division of Angiology, Department of Internal Medicine II, Medical University of Vienna, Vienna, Austria
Sabine Steiner

³Division of Angiology, Department of Internal Medicine II, Medical University of Vienna, Vienna, Austria

Abstract

Summary

Chronic heart failure (CHF) is characterised by activation of neuroendocrine and inflammatory pathways, and both are linked to a prothrombotic state. Treatment with omega-3 polyunsaturated fatty acids (n3-PUFA) showed significant benefits including mortality reduction in CHF, but exact mechanisms of action are still unclear. We investigated the effects of n3-PUFA on markers of platelet activation and thrombogenesis in patients with severe CHF. Thirty-six patients with non-ischaemic CHF (LVEF<35%, NYHA class>2) under optimised therapy were randomised to supplementation with 1g/day or 4g/day n3-PUFA, or placebo for 12 weeks. Using whole-blood flow cytometry, monocyteplatelet aggregates characterised by CD14+/CD42b+ co-expression and monocytic tissue factor (TF) were determined. Plasma levels of P-selectin, sCD40L, fibrinogen, prothrombin fragment F1.2, TF and proinflammatory markers (high sensitive[hs] interleukin-6, hsCRP, hsTNFalpha, monocyte chemotactic protein-1) were measured by immunoassay. Supplementation with 1g/day and 4g/day n3-PUFA but not placebo significantly reduced monocyte-platelet aggregates in a dose-dependent manner (p for trend=0.02 across the groups). A dose of 4g/day but not 1g/day n3-PUFA significantly decreased P-selectin (p=0.03). Plasma TF decreased dose-dependently upon n3-PUFA supplementation (p for trend=0.02), paralleled by a significant decrease of TF+-monocytes (p for trend=0.01). The amount of 4g/day n3-PUFA exhibited modest anti-inflammatory effects with a significant reduction of hs interleukin-6 (p<0.01) and a trend-wise reduction of hsTNF-alpha (p=0.09). No changes were seen for sCD40L, fibrinogen, hsCRP and monocyte chemotactic protein-1, while F1.2 was decreased by 4g/day n3-PUFA (P=0.03). In patients with severe non-ischaemic CHF, treatment with n3-PUFA leads to a dose-dependent decrease of platelet activation and TF. Higher dosage exhibits also anti-inflammatory effects.

* ClinicalTrials.gov registration number: NCT00149409

Keywords

Fatty acids - heart failure - inflammation - platelets - tissue factor

Full Text

References

References
1 Chong AY, Lip GY. Viewpoint: the prothrombotic state in heart failure: a maladaptive inflammatory response?. Eur J Heart Fail 2007; 9: 124-128.
2 de Peuter OR, Kok WE, Torp-Pedersen C. et al. Systolic heart failure: a prothrombotic state. Semin Thromb Hemost 2009; 35: 497-504.
3 Marcucci R, Gori AM, Giannotti F. et al. Markers of hypercoagulability and inflammation predict mortality in patients with heart failure. J Thromb Haemost 2006; 4: 1017-1022.
4 Shantsila E, Lip GY. The endothelium and thrombotic risk in heart failure. Thromb Haemost 2009; 102: 185-187.
5 Freudenberger RS, Schumaecker MM, Homma S. What is the appropriate approach to prevention of thromboembolism in heart failure?. Thromb Haemost 2010; 103: 489-495.
6 Tavazzi L, Maggioni AP, Marchioli R. et al. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 2008; 372: 1223-1230.
7 Lavie CJ, Milani RV, Mehra MR. et al. Omega-3 polyunsaturated fatty acids and cardiovascular diseases. J Am Coll Cardiol 2009; 54: 585-594.
8 Di Minno MN, Tremoli E, Tufano A. et al. Exploring newer cardioprotective strategies: omega-3 fatty acids in perspective. Thromb Haemost 2010; 104: 664-680.
9 Calder PC. Polyunsaturated fatty acids and inflammation. Prostaglandins Leukot Essent Fatty Acids 2006; 75: 197-202.
10 Moertl D, Hammer A, Steiner S. et al. Dose-Dependent Effects of Omega-3-Poly-unsaturated Fatty Acids on Systolic Left Ventricular Function, Endothelial Function, and Markers of Inflammation in Chronic Heart Failure of Non-Ischemic Origin. Am Heart J 2011; 161: 915 e1-e9.
11 Steiner S, Speidl WS, Pleiner J. et al. Simvastatin blunts endotoxin-induced tissue factor in vivo. Circulation 2005; 111: 1841-1846.
12 Gibbs CR, Blann AD, Watson RD. et al. Abnormalities of hemorheological, endothelial, and platelet function in patients with chronic heart failure in sinus rhythm: effects of angiotensin-converting enzyme inhibitor and beta-blocker therapy. Circulation 2001; 103: 1746-1751.
13 Chin BS, Blann AD, Gibbs CR. et al. Prognostic value of interleukin-6, plasma viscosity, fibrinogen, von Willebrand factor, tissue factor and vascular endothelial growth factor levels in congestive heart failure. Eur J Clin Invest 2003; 33: 941-948.
14 Jug B, Vene N, Salobir BG. et al. Prognostic impact of haemostatic derangements in chronic heart failure. Thromb Haemost 2009; 102: 314-320.
15 Chung I, Choudhury A, Patel J. et al. Soluble, platelet-bound, and total P-selectin as indices of platelet activation in congestive heart failure. Ann Med 2009; 41: 45-51.
16 Lee KW, Lip GY. Effects of lifestyle on hemostasis, fibrinolysis, and platelet reactivity: a systematic review. Arch Intern Med 2003; 163: 2368-2392.
17 Din JN, Harding SA, Valerio CJ. et al. Dietary intervention with oil rich fish reduces platelet-monocyte aggregation in man. Atherosclerosis 2008; 197: 290-296.
18 Tuleta I, Bauriedel G, Hasenbank I. et al. Antiplatelet effects of n-3 polyunsaturated fatty acids compared with aspirin: a pilot study with whole-blood aggregometry. Thromb Res 2009; 124: 724-726.
19 Larson MK, Ashmore JH, Harris KA. et al. Effects of omega-3 acid ethyl esters and aspirin, alone and in combination, on platelet function in healthy subjects. Thromb Haemost 2008; 100: 634-641.
20 Cerbone AM, Cirillo F, Coppola A. et al. Persistent impairment of platelet aggregation following cessation of a short-course dietary supplementation of moderate amounts of N-3 fatty acid ethyl esters. Thromb Haemost 1999; 82: 128-133.
21 von Schacky C, Weber PC. Metabolism and effects on platelet function of the purified eicosapentaenoic and docosahexaenoic acids in humans. J Clin Invest 1985; 76: 2446-2450.
22 Calder PC. n-3 Fatty acids and cardiovascular disease: evidence explained and mechanisms explored. Clin Sci (Lond) 2004; 107: 1-11.
23 Eschen O, Christensen JH, De Caterina R. et al. Soluble adhesion molecules in healthy subjects: a dose-response study using n-3 fatty acids. Nutr Metab Cardiovasc Dis 2004; 14: 180-185.
24 Lee KW, Blann AD, Lip GY. Effects of omega-3 polyunsaturated fatty acids on plasma indices of thrombogenesis and inflammation in patients post-myocardial infarction. Thromb Res 2006; 118: 305-312.
25 Eschen O, Christensen JH, MT LAR. et al. Effects of marine n-3 fatty acids on circulating levels of soluble adhesion molecules in patients with chronic heart failure. Cell Mol Biol (Noisy-le-grand) 2010; 56: 45-51.
26 Michelson AD, Barnard MR, Krueger LA. et al. Circulating monocyte-platelet aggregates are a more sensitive marker of in vivo platelet activation than platelet surface P-selectin: studies in baboons, human coronary intervention, and human acute myocardial infarction. Circulation 2001; 104: 1533-1537.
27 Lievens D, Eijgelaar WJ, Biessen EA. et al. The multi-functionality of CD40L and its receptor CD40 in atherosclerosis. Thromb Haemost 2009; 102: 206-214.
28 Stumpf C, Lehner C, Eskafi S. et al. Enhanced levels of CD154 (CD40 ligand) on platelets in patients with chronic heart failure. Eur J Heart Fail 2003; 5: 629-637.
29 Ueland T, Aukrust P, Yndestad A. et al. Soluble CD40 ligand in acute and chronic heart failure. Eur Heart J 2005; 26: 1101-1107.
30 Stumpf C, Lehner C, Raaz D. et al. Platelets contribute to enhanced MCP-1 levels in patients with chronic heart failure. Heart 2008; 94: 65-69.
31 Chung I, Choudhury A, Patel J. et al. Soluble CD40L, platelet surface CD40L and total platelet CD40L in congestive heart failure: relationship to platelet volume, mass and granularity. J Intern Med 2008; 263: 313-321.
32 Yan JC, Liu PJ, Du RZ. et al. Relationship between CD40 ligand expression and B type natriuretic peptide levels in patients with chronic heart failure. Clin Chim Acta 2008; 392: 17-20.
33 Catellier DJ, Aleksic N, Folsom AR. et al. Atherosclerosis Risk in Communities (ARIC) Carotid MRI flow cytometry study of monocyte and platelet markers: in-traindividual variability and reliability. Clin Chem 2008; 54: 1363-1371.
34 Aarsetoy H, Brugger-Andersen T, Hetland O. et al. Long term influence of regular intake of high dose n-3 fatty acids on CD40-ligand, pregnancy-associated plasma protein A and matrix metalloproteinase-9 following acute myocardial infarction. Thromb Haemost 2006; 95: 329-336.
35 Nieuwenhuys CM, Beguin S, Offermans RF. et al. Hypocoagulant and lipid-lowering effects of dietary n-3 polyunsaturated fatty acids with unchanged platelet activation in rats. Arterioscler Thromb Vasc Biol 1998; 18: 1480-1489.
36 Vanschoonbeek K, Feijge MA, Paquay M. et al. Variable hypocoagulant effect of fish oil intake in humans: modulation of fibrinogen level and thrombin generation. Arterioscler Thromb Vasc Biol 2004; 24: 1734-1740.
37 Marckmann P, Bladbjerg EM, Jespersen J. Dietary fish oil (4 g daily) and cardiovascular risk markers in healthy men. Arterioscler Thromb Vasc Biol 1997; 17: 3384-3391.
38 Del Turco S, Basta G, Lazzerini G. et al. Effect of the administration of n-3 poly-unsaturated fatty acids on circulating levels of microparticles in patients with a previous myocardial infarction. Haematologica 2008; 93: 892-899.
39 Tremoli E, Eligini S, Colli S. et al. n-3 fatty acid ethyl ester administration to healthy subjects and to hypertriglyceridemic patients reduces tissue factor activity in adherent monocytes. Arterioscler Thromb 1994; 14: 1600-1608.
40 Grundt H, Hetland O, Nilsen DW. Changes in tissue factor and activated factor XII following an acute myocardial infarction were uninfluenced by high doses of n-3 polyunsaturated fatty acids. Thromb Haemost 2003; 89: 752-759.
41 Seljeflot I, Hurlen M, Arnesen H. Increased levels of soluble tissue factor during long-term treatment with warfarin in patients after an acute myocardial infarction. J Thromb Haemost 2004; 2: 726-730.
42 Lindmark E, Tenno T, Siegbahn A. Role of platelet P-selectin and CD40 ligand in the induction of monocytic tissue factor expression. Arterioscler Thromb Vasc Biol 2000; 20: 2322-2328.

Supplementary Material

Online Supplementary Material (PDF) (PDF) (opens in new window)